Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 1;29(5):1227-1234.
doi: 10.1093/annonc/mdy085.

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer

J Smeby  1 , A Sveen  2 , M A Merok  3 , S A Danielsen  2 , I A Eilertsen  2 , M G Guren  4 , R Dienstmann  5 , A Nesbakken  6 , R A Lothe  7
Affiliations

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer

J Smeby et al. Ann Oncol. .

Abstract

Background: The prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer (CRC) varies with microsatellite instability (MSI) status. The gene expression-based consensus molecular subtypes (CMSs) of CRC define molecularly and clinically distinct subgroups, and represent a novel stratification framework in biomarker analysis. We investigated the prognostic value of these mutations within the CMS groups.

Patients and methods: Totally 1197 primary tumors from a Norwegian series of CRC stage I-IV were analyzed for MSI and mutation status in hotspots in KRAS (codons 12, 13 and 61) and BRAF (codon 600). A subset was analyzed for gene expression and confident CMS classification was obtained for 317 samples. This cohort was expanded with clinical and molecular data, including CMS classification, from 514 patients in the publically available dataset GSE39582. Gene expression signatures associated with KRAS and BRAFV600E mutations were used to evaluate differential impact of mutations on gene expression among the CMS groups.

Results: BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild-type: Hazard ratio (HR) 2.85, P < 0.001; KRAS mutation versus KRAS/BRAF wild-type: HR 1.30, P = 0.013). BRAFV600E-mutated MSS tumors were strongly enriched and associated with metastatic disease in CMS1, leading to negative prognostic impact in this subtype (OS: BRAFV600E mutation versus wild-type: HR 7.73, P = 0.001). In contrast, the poor prognosis of KRAS mutations was limited to MSS tumors with CMS2/CMS3 epithelial-like gene expression profiles (OS: KRAS mutation versus wild-type: HR 1.51, P = 0.011). The subtype-specific prognostic associations were substantiated by differential effects of BRAFV600E and KRAS mutations on gene expression signatures according to the MSI status and CMS group.

Conclusions: BRAFV600E mutations are enriched and associated with metastatic disease in CMS1 MSS tumors, leading to poor prognosis in this subtype. KRAS mutations are associated with adverse outcome in epithelial (CMS2/CMS3) MSS tumors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prognostic impact of KRAS and BRAFV600E mutations in unstratified Oslo-series and according to MSI status. Kaplan–Meier survival curves showing 5-year overall survival (OS) for tumors with KRAS and BRAFV600E mutations versus KRAS/BRAF wild-type in (A) the unstratified Oslo-series and (B) stratified according to MSI status. See supplementary Figure S5, available at Annals of Oncology online for analyses of 5-year relapse-free survival.
Figure 2.
Figure 2.
BRAF V600E and KRAS mutations are associated with poor patient prognosis in specific CMS groups. (A) In 737 patients with stages I–IV CRC from two independent series (Oslo-series and GSE39582), 35 (5%) had MSS tumors of the CMS1 subtype. Among these patients, BRAFV600E mutations were associated with a poor OS (left panel). No prognostic impact of BRAFV600E mutations was seen in 97 patients with MSI tumors of the CMS1 subtype. (B) In the same set of patients, 341 (46%) had MSS tumors of the CMS2 subtype. Here, KRAS mutations were associated with a poor survival. (C) Analyzing undifferentiated (CMS1 and 4) and epithelial (CMS2 and 3) tumors within the MSS phenotype revealed KRAS mutations to have poor prognostic impact limited to epithelial tumors.
See this image and copyright information in PMC

References

    1. Moertel CG, Fleming TR, Macdonald JS. et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122(5): 321–326. - PubMed
    1. Sepulveda AR, Hamilton SR, Allegra CJ. et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn 2017; 19(2): 187–225. - PMC - PubMed
    1. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E.. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46(15): 2788–2798. - PubMed
    1. Sinicrope FA, Shi Q, Allegra CJ. et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol 2017; 3(4): 472–480. - PMC - PubMed
    1. Samowitz WS, Sweeney C, Herrick J. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65(14): 6063–6069. - PubMed

Publication types

MeSH terms